

PRESS RELEASE

CORDLIFE PHILIPPINES LAUNCHES UMBILICAL CORD TISSUE BANKING

- ***Additional option for storing of children's stem cells allows child and family to have access to wider range of future medical treatments***
- ***Capitalise on fast rising Philippines middle class, where per capita disposable income is projected to increase 157% from 2007 to 2015***
- ***In line with Cordlife's growth plans to offer complementary services to its clients***

Singapore, 12 August 2013 – Cordlife Medical Philippines, Inc. (“Cordlife Philippines”), a wholly-owned subsidiary of **Cordlife Group Limited** (“Cordlife”, and together with its subsidiaries, the “Group”), a leading cord blood and tissue banking service provider, announced on 6 August 2013 that it officially launched its newest service, umbilical cord tissue banking in the Philippines. The offering allows expectant parents to store their newborn's umbilical cord, and the stem cells it contains, for potential use in future therapeutic applications.

Mr Jeremy Yee, Executive Director and Chief Executive Officer of Cordlife said, “The introduction of umbilical cord tissue banking in Philippines represents the latest milestone for Cordlife, one which reflects our dedication to introducing pioneering products and services to our customers. We take great pride in offering Filipino parents the additional option of storing their child's cord tissue to help them further safeguard their family's future.”

According to Dr. Arvin Faundo, Medical Director of Cordlife Philippines, the umbilical cord is abundant with two types of stem cell, epithelial stem cells (EpSCs) and mesenchymal stem cells (MSCs), which hold immense potential in repairing injured tissues and organs as well as treating various diseases.

The initial public offering of Cordlife's shares was sponsored by PrimePartners Corporate Finance Pte. Ltd., who assumes no responsibility for the contents of this release.

Epithelial stem cells (EpSCs) form the soft tissues that connect, support or surround other structures and organs of the body including cornea and skin, as well as lining of the stomach and liver. Based on current research, EpSCs are considered to be a possible key resource for epidermal and skin regeneration as they have been used to treat surface ulcers, burns and tissue trauma such as those from accidents. They are also being studied in regenerative medicine for corneal replacement.

Mesenchymal stem cells (MSCs), meanwhile, are the building blocks of the structural tissues of the human body such as bone, cartilage, muscle, fibrous tissues and fat. More than 280¹ clinical trials are on-going worldwide to uncover the potential applications of MSCs, including tissue repair in heart failure, cartilage injury, stroke, spinal cord injury, amyotrophic lateral sclerosis, Parkinson's disease and multiple sclerosis, as well as supporting hematopoietic stem cell (HSC) transplantation² by reducing immune system complications and shortening time to engraftment.

Both EpSCs and MSCs are abundant in the umbilical cord, whereas cord blood is a proven source of hematopoietic (HSCs) or blood-forming stem cells used in the treatment of certain cancers, blood disorders and immune-deficiencies. MSCs can also be found in cord blood, though in much smaller quantities.

“Banking the umbilical cord tissue, which is rich in EpSCs and MSCs, will allow the child and his/her family to have ready access to a lot more medical options in the future,” commented Dr. Faundo.

Cordlife Philippines was first established in January 2006 as a marketing office. In February 2010, Cordlife Philippines officially opened the country's first and only ISO9001:2008 certified cord blood processing and storage facility. Located in UP-Ayalaland Technohub in Quezon City, the facility in Philippines has a storage capacity of more than 20,000 cord blood units, and uses liquid nitrogen for long-term

¹ ClinicalTrials.gov. Accessed on 24 April 2013. (<http://www.clinicaltrials.gov/ct2/results?term=mesenchymal+stem+cells>)

² Battiwalla M, Hematti P. 2010. Cytotherapy. 1 January 2010.

cryopreservation. The highly-secure world-class facility operates 365 days a year and offers the world's only fully automated cord blood processing system, SEPAX[®].

Moreover, unlike other stem cell banks, Cordlife cryopreserves stem cells in its original form, allowing superior quality cells to be derived for future medical therapy. This also lets families take advantage of future advancements in stem cell technology.

According to a 10 April 2013 report by Deloitte & Touche Financial Advisory Services Limited ("the Deloitte report"), Philippines represents one of the high growth Asean markets with a burgeoning middle class, where per capita disposable income is projected to increase 157% from 2007 to 2015. Philippines also has a large population base of 102 million as of 2011, which is expected to reach 110 million in 2015.

The fast-rising middle class in Philippines are becoming increasingly aware of the benefits of stem cells storage for their children as shown by the 2007–2011 Compound Annual Growth Rate of annual incremental storage units for private cord blood banks of 35%. Umbilical cord tissue banking is a natural extension of Filipino parents' for better healthcare options for their children.

Mr Yee continued: "At the heart of umbilical cord tissue banking is helping parents secure their child's future well-being. Cordlife, with its expertise and access to best-available technology, allows them to do exactly this, preparing for any eventuality and safeguarding their family's health. With the launch of this new service, we are confident of increasing our share of the cord tissue banking business in the fast growing Philippines market."

- The End -

ABOUT CORDLIFE GROUP LIMITED (Bloomberg stock code: CLGL)

Incorporated in May 2001, Cordlife Group Limited (“Cordlife”, and together with its subsidiaries, the “Group”), is an established cord blood and tissue banking service provider. Amongst the first private cord blood banks in Asia, Cordlife has established a dominant market leader position in Singapore³. Today, it has the larger market share of the only two private cord blood banks in Singapore. In Hong Kong, it is amongst the three market leaders for private cord blood banks. Cordlife completed the acquisition of the cord blood and cord tissue banking businesses and assets in India, the Philippines and Indonesia from Australia-listed Cordlife Limited in June 2013.

Cordlife collects, processes, tests, cryopreserves and stores stem cells from the umbilical cord blood of the child at birth, allowing customers to preserve their child’s cord blood stem cells for treatment later in his or her life if their child so requires. In March 2011, the Group launched umbilical cord tissue banking service in Hong Kong, offering an additional service that allows customers to collect and store their child’s umbilical cord tissue, which is a rich source of mesenchymal and epithelial stem cells and may potentially help repair the body in different ways. In May 2013, Cordlife Technologies Pte Ltd, a wholly-owned subsidiary of Cordlife Group Limited, launched umbilical cord tissue banking service in Singapore. The storage and banking of umbilical cord tissue services provided in Singapore is currently not licensed by the Ministry of Health, Singapore. This service is provided on a research/clinical trial basis.

Cordlife’s business model, which allows customers to opt for a one-time lump sum payment, or annual payments until the child reaches maturity (21 years old in Singapore and 18 years old in Hong Kong), provides the Group with a stable pool of recurring cash flow.

In addition, Cordlife, through its collaborative relationships or arrangements with major private hospitals and clinics such as Thomson Medical and Parkway East Hospital, has continued to increase public awareness of its cord blood banking services in Singapore. Overseas, the Group has a 10% direct stake in China Cord Blood Corporation – a top

³ Source : Deloitte & Touche Financial Advisory Services Limited report, 10 April 2013

operator in China holding majority shares in the Beijing, Guangdong and Zhejiang Cord Blood Banks, and an approximately 20% share in Shandong Cord Blood Bank.

Cordlife has been accredited since 2005 by AABB (formerly known as the American Association of Blood Banks), an association involved in the field of transfusion medicine and cellular therapies. The Group is one of the first private cord blood banks in Singapore and amongst the first in Hong Kong to have released cord blood units for transplants and other therapeutic use. In Singapore, Cordlife was the first private cord blood bank to release cord blood units for the treatment of cerebral palsy.

Cordlife's track record has won the Group many accolades and awards, including: Best Medical Service Award 2010 by Capital CEO Supreme Brand Awards; Top Pregnant/Baby Products Award 2011 by Pregnancy Magazine; Outstanding Financial Strength Cord Blood Bank 2012 by Quamnet Outstanding Enterprise Awards; Most Popular Brand Award 2010 – The Most Popular Cord Blood Bank by TVB Weekly; and U-Choice Lifestyle Brand Award 2010 by Metroinfo FM99.7⁴. In October 2012, Cordlife was awarded the prestigious SIAS Investors' Choice Awards as runner-up in the "Most Transparent Company Award 2012" New Issues Category.

ISSUED ON BEHALF OF	:	Cordlife Group Limited
BY	:	Financial PR Pte Ltd 4 Robinson Road #04-01 The House of Eden Singapore 048543
CONTACT	:	Mr Gabriel Tan / Mr Kamal Samuel
OFFICE	:	6438-2990
EMAIL	:	gabriel@financialpr.com.sg / kamal@financialpr.com.sg

⁴ Awarded to Cordlife Hong Kong